News of Note—Stent trial controversy, Corindus funding and more

(NS Newsflash/CC BY 2.0)

> Controversy has engulfed a long-running study into the use of stents in patients with stable ischemic heart disease. The row blew up after investigators changed the primary endpoint late in the study. CardioBrief

> Corindus, a provider of robotic-assisted vascular intervention technologies, has put together a $25 million private placement. Statement

> Nexstim has ended negotiations with a potential Chinese distribution partner. The neuromodulation company had hoped to receive a $1.2 million investment through the deal. Release


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Suggested Articles

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Exact Sciences received an FDA breakthrough designation for its liver cancer blood test as it finalized its $2.8 billion merger with Genomic Health.